The trial may have contained a tough sample group.

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

An archaeologist in Sweden spent three years traveling in vessels built like those from 1,000 years ago. He discovered lost ...

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to ...

Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill.

As the late summer sun beat down on a national park in Norway, archaeologists trekked across the glacial landscape, scouring ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

After a dominating all-around performance against the Houston Texans, the Minnesota Vikings followed it up with a mediocre ...